IASO BioMed Announces Addition of Four Members to Its Scientific Advisory Board
November 13, 2018 09:00 ET
|
IASO BioMed, Inc.
Company developing a Next Generation Treatment for Low Testosterone CENTENNIAL, Colo., Nov. 13, 2018 (GLOBE NEWSWIRE) -- IASO BioMed, Inc. (“IASO” or the “Company”), an innovative biotechnology...
Diet Doc Partners with AMG to Offer Bioidentical Hormone Replacement Therapy to Patients Nationwide
February 10, 2016 04:05 ET
|
Diet Doc Diet and Weight Loss
HOUSTON, Feb. 10, 2016 (GLOBE NEWSWIRE) -- The side effects of hormonal imbalance are plentiful, causing a range of symptoms from fatigue, depression, headaches and even reduced libido. Hormones can...
Clarus Therapeutics Top-line Results Show Oral Testosterone Replacement Candidate, CLR-610, Meets Phase 3 Study Primary Efficacy Endpoint
September 25, 2012 08:00 ET
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill, Sept. 25, 2012 (GLOBE NEWSWIRE) -- Clarus
Therapeutics, Inc., today reported top-line results from the
Company's ongoing Phase 3 study of
CLR-610, the Company's proprietary oral...
Clarus Therapeutics Strengthens Patent Estate with Issuance of a U.S. Patent Directed to Formulations and Method of Use of Clarus' Oral Testosterone Product
September 19, 2012 08:00 ET
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill, Sept. 19, 2012 (GLOBE NEWSWIRE) -- Clarus Therapeutics,
Inc., today announced that the U.S. Patent and Trademark Office
issued U.S. Patent No. 8,241,664 entitled, "Pharmaceutical...